Preclinical proof of principle for orally delivered Th17 antagonist miniproteins.
Berger S, Seeger F, Yu TY, Aydin M, Yang H, Rosenblum D, Guenin-Macé L, Glassman C, Arguinchona L, Sniezek C, Blackstone A, Carter L, Ravichandran R, Ahlrichs M, Murphy M, Pultz IS, Kang A, Bera AK, Stewart L, Garcia KC, Naik S, Spangler JB, Beigel F, Siebeck M, Gropp R, Baker D.
Berger S, et al. Among authors: pultz is.
Cell. 2024 Aug 8;187(16):4305-4317.e18. doi: 10.1016/j.cell.2024.05.052. Epub 2024 Jun 26.
Cell. 2024.
PMID: 38936360
Free article.